Table of Contents
A patent invalidation Ghent litigation team can rely on has to reflect where the disputes come from — and in Ghent they come from biotech. The city sits in Flanders, the Dutch-speaking north of Belgium, and anchors one of Europe’s leading plant- and industrial-biotechnology clusters around Ghent University and VIB, the Flanders Institute for Biotechnology. Plant-science, agrifood and materials patents are the local litigation theme. Yet a Ghent dispute is never tried in Ghent: Belgian law gives the Brussels Enterprise Court exclusive national jurisdiction over patent validity, and Belgium is a full member of the Unified Patent Court. PerspireIP builds invalidity-grade searches for the accused parties and counsel fighting those patents across Belgium, the EPO and the UPC.
Where a patent invalidation Ghent case is actually heard
Belgium concentrates all patent litigation in a single forum. Under Article XI.337 of the Code of Economic Law, in force since 1 January 2015, the Brussels Enterprise Court (Ondernemingsrechtbank Brussel / Tribunal de l’entreprise de Bruxelles) holds exclusive national jurisdiction over patent infringement and over nullity (invalidity) actions. Appeals go to the Brussels Court of Appeal. A dispute rooted in Ghent — over a plant-biotech trait, an enzyme process or an agrifood formulation — is still filed and tried in Brussels. There is no patent venue in Ghent or anywhere else in Flanders.
That single-court design makes the prior art decisive. In a Belgian nullity action the accused party asks the Brussels court to revoke the patent for lack of novelty or inventive step, and the outcome turns on what was publicly available before the priority date. Whether the fight is a defensive counterclaim to an infringement suit or a standalone nullity action, the invalidity search is the engine of the case.
- Brussels Enterprise Court — exclusive first-instance court for Belgian infringement and nullity, since 1 January 2015
- Brussels Court of Appeal — hears all Belgian patent appeals
- EPO Opposition Division — central attack on a European patent within nine months of grant
- Unified Patent Court — revocation of unitary and non-opted-out European patents, with a Brussels Local Division
The UPC Brussels Local Division: Ghent’s differentiator
Belgium is not a UPC bystander. It ratified the Agreement on a Unified Patent Court in 2014 and hosts a Brussels Local Division of the UPC, seated in the Federal Public Service Economy building on Rue du Progrès. That matters for a Ghent-based defendant in a way it does not for parties in non-UPC states such as Spain or Poland: a European patent with unitary effect, or a classical European patent that has not been opted out, can be enforced against — and revoked in — a single UPC action covering all participating states at once.
The Brussels Local Division accepts Dutch, French, German and English as languages of proceedings, so a Flemish company can litigate in Dutch or shift to English to match the patent. An accused party can raise invalidity as a counterclaim inside an infringement suit before the Local Division, or file a standalone revocation action in the UPC Central Division. Either way, the case is decided on novelty and inventive step — the same questions a strong prior-art search answers.
Ghent’s biotech and agrifood cluster: where the patent fights come from
Ghent hosts one of Europe’s largest agro-biotech campuses. Ghent University and VIB, the Flanders Institute for Biotechnology, built the VIB Center for Plant Systems Biology into an internationally leading plant-science hub, with more than a thousand people working in plant biotechnology alone. Spin-offs and majors clustered around it — Biotalys, Aphea.Bio, the BASF Innovation Center Gent and Syngenta — turn basic research into patented traits, biologicals and crop-protection products.
The reach is not only plant science. VIB and Ghent University also drive industrial biotechnology, enzymes, fermentation and biomolecular medicine, while the wider Ghent economy adds materials, chemistry and agrifood processing. The result: local patent disputes cluster around genes and sequences, biological actives, fermentation processes and formulations — subject-matter where validity is won or lost on non-patent literature, not on consumer-tech patents.
Where biotech, plant-science and agrifood prior art lives
Life-science and chemistry patents are anticipated in a different literature than electronics or software. A great deal of the decisive art never appears in a patent database at all — it lives in the journal record and in specialist sequence and compound collections. A credible invalidity search in this field has to reach those sources and prove the public-availability date of each one.
- Sequence and structure databases for gene, protein, peptide and nucleic-acid claims, where a Ghent trait may have been disclosed years earlier
- Chemical Abstracts (CAS) and the peer-reviewed journal literature, where a compound, enzyme or synthesis may first be published
- Older or abandoned patent families, argued as inventive-step (obviousness) combinations under the EPO problem-and-solution approach
- Conference abstracts, PhD theses and dated technical disclosures — common in an academic hub like Ghent University — that predate the priority date
For a plant-biotech or fermentation claim the anticipating reference is frequently an older paper, a public sequence deposit or an abandoned family, not the headline patent. We treat dating as evidence to be proved — establishing that each reference was genuinely public before the priority date the claim actually relies on.
Three routes to attack the patent: Brussels nullity, EPO opposition, UPC revocation
An accused party in Ghent usually has more than one way to attack a patent, and they are not interchangeable. A Belgian nullity action runs before the Brussels Enterprise Court and revokes the Belgian designation of the patent. EPO opposition is a central attack: filed within nine months of grant, it can knock out the European patent in every designated state at once, decided on novelty and inventive step.
Because Belgium is in the UPC, there is a powerful third route. A UPC revocation action — as a Central Division standalone or as a counterclaim before the Brussels Local Division — can kill a unitary patent, or a non-opted-out European patent, across all participating states in one judgment. That option is simply not available in non-UPC countries, and it changes the strategic calculus for a Flemish defendant weighing a national fight against a pan-European one.
The routes share one dependency: prior art. One rigorous patent invalidation Ghent search, charted claim by claim, can feed a Brussels nullity counterclaim, an EPO opposition and a UPC revocation at the same time, so the same evidence works across every forum.
Why Ghent’s own courts don’t hear patents — and why it doesn’t matter
Ghent has its own courts and a Court of Appeal seat, and it is the second-largest city of Flanders. None of that gives it a patent forum. Belgian patent venue is a separate, specialised system: infringement and validity go to the Brussels Enterprise Court, European patents are opposed at the EPO in Munich, and unitary or non-opted-out patents are revoked at the UPC. Being headquartered in Ghent confers no local patent jurisdiction.
Registration is equally centralised. The Belgian Office for Intellectual Property (OPRI/DIE), part of the Federal Public Service Economy in Brussels, grants Belgian patents but does not examine them on the merits — it relies on an EPO-style novelty search rather than a full grant examination. That light-touch grant means Belgian national patents can be more vulnerable on validity, which is exactly where a disciplined prior-art search earns its keep. What decides a validity fight is the strength and dating of the art — a sequence deposit, an older paper, an abandoned family — not a Ghent address.
How PerspireIP builds a patent invalidation Ghent case can rely on
Every engagement follows the same disciplined path. We map the asserted claims element by element, fix the priority date that actually governs each one, and search against that date rather than the filing date on the cover. For plant-biotech, agrifood and chemistry subject-matter we run patent and deep non-patent-literature searching in parallel — sequence and structure databases, CAS, journals and older patent families — then build claim charts a Brussels judge, an EPO Opposition Division or a UPC panel can follow.
- Claim charting mapped to novelty and inventive step under the EPC and Belgian law
- Deep retrieval across sequence databases, CAS, peer-reviewed journals and older patent families
- Public-availability dating for every reference, evidenced in Dutch, French, German and English
- Prior art sized to your forum — a Brussels nullity action, the nine-month EPO opposition window, or UPC revocation
- A written invalidity analysis and reference packages ready for the Brussels court, the EPO or the UPC
We work alongside your Belgian and European counsel as a specialist search partner, deliver to Brussels, EPO and UPC deadlines, and keep every engagement confidential. Whether you are a Flanders biotech facing an assertion, an agrifood or generics entrant clearing a path, or litigation counsel preparing a UPC defence, we scale to fit — a single search, a multi-patent campaign or ongoing support. Send us the patent number and your key dates, and we will scope a patent invalidation Ghent project within one business day.
IP Landscape & Resources in Ghent
Key intellectual-property authorities and venues relevant to Ghent:
- Belgian Office for Intellectual Property (OPRI/DIE) — the Belgian patent office within the Federal Public Service Economy; grants Belgian patents without a full merits examination
- European Patent Office (EPO) — grants European patents and runs post-grant opposition, a central attack filed within nine months of grant
- Unified Patent Court (UPC) — hears revocation of unitary and non-opted-out European patents; Belgium hosts a Brussels Local Division
- FPS Justice (Belgium) — the Belgian justice system under which the Brussels Enterprise Court holds exclusive jurisdiction over patent disputes
Request a Patent Invalidation Search in Ghent
Request a Patent Invalidation Search in Ghent
Get an invalidity-grade prior-art search built for a Brussels nullity action, a nine-month EPO opposition, or UPC revocation before the Brussels Local Division, tuned for Ghent’s plant-biotech, agrifood and materials claims. Send us the patent number and your key dates, and we will scope the work within one business day.
Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.
Frequently Asked Questions
Why is a Ghent patent case litigated in Brussels, not Ghent?
Because Article XI.337 of the Belgian Code of Economic Law gives the Brussels Enterprise Court exclusive national jurisdiction over patent infringement and nullity actions, in force since 1 January 2015, with appeals to the Brussels Court of Appeal. There is no patent venue in Ghent or anywhere else in Flanders, so a dispute arising from a Ghent biotech or agrifood patent is still filed and tried in Brussels. Ghent’s own courts do not hear patent validity cases; venue is a separate, specialised national system.
Belgian nullity, EPO opposition or UPC revocation — which route invalidates the patent?
They do different things. A Belgian nullity action before the Brussels Enterprise Court revokes only the Belgian designation. EPO opposition, filed within nine months of grant, is a central attack that can revoke the European patent in all designated states at once. Because Belgium is in the UPC, a UPC revocation action — via the Central Division or as a counterclaim before the Brussels Local Division — can kill a unitary patent, or a non-opted-out European patent, across participating states in one judgment. One prior-art search can feed all three.
Does Belgium’s membership in the Unified Patent Court change a Ghent defendant’s options?
Yes, significantly. Belgium ratified the UPC Agreement in 2014 and hosts a Brussels Local Division accepting Dutch, French, German and English. Unlike a defendant in a non-UPC state such as Spain or Poland, a Ghent company can face — and challenge — a single UPC action covering every participating state for a unitary or non-opted-out European patent. That makes a pan-European revocation possible in one forum, so invalidity strategy has to weigh a national Brussels fight against a UPC-wide one from the outset.
Where does biotech and agrifood prior art actually live?
Often outside patent databases. The decisive art for a plant-biotech, enzyme or formulation claim frequently sits in sequence and structure databases, in the journal literature indexed by Chemical Abstracts (CAS), and in older or abandoned patent families argued as inventive-step combinations. Conference abstracts and PhD theses from an academic hub like Ghent University matter too. We search those sources directly and prove each reference was public before the claim’s priority date, which is what a Brussels court, the EPO or the UPC requires.